武田制药-话题@MedSci - williamhill asia

#武田制药#

8篇内容 | 1074人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2133719, encodeId=19f32133e19e0, content=2021年1月20日，国家药监局正式批准日本<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>的1类降压新药<a href='/topic/show?id=a968104e21cf' target=_blank style='color:#2F92EE;'>#美阿沙坦#</a>钾片（商品名称: 易达比）在我国上市，5月份，美阿沙坦正式进入临床使用，用于治疗<a href='/topic/show?id=c1e83e138a7' target=_blank style='color:#2F92EE;'>#原发性高血压#</a>。这是目前认为疗效最强的<a href='/topic/show?id=1e259815580' target=_blank style='color:#2F92EE;'>#降压药物#</a> , objectTitle=最强降压药美阿沙坦在我国重磅上市！高血压患者福音, objectType=article, longId=739739, objectId=47b0e3973921, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20220915/b4c963935f6b4427b550616159687aee.jpg, objectUrl=/article/show_article.do?id=47b0e3973921, replyNumber=1, likeNumber=78, createdTime=2023-05-14, rootId=0, userName=侠胆医心, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=47b0e3973921, moduleTitle=最强降压药美阿沙坦在我国重磅上市！高血压患者福音, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=47b0e3973921)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957015, encodeId=f975195e01564, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头, objectType=article, longId=295366, objectId=43d6295366c1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=43d6295366c1, replyNumber=0, likeNumber=66, createdTime=2022-08-22, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=43d6295366c1, moduleTitle=武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=43d6295366c1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957014, encodeId=b4e9195e01433, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, objectType=article, longId=211778, objectId=aba2211e7815, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aba2211e7815, replyNumber=0, likeNumber=81, createdTime=2021-05-30, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aba2211e7815, moduleTitle=武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=aba2211e7815)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957013, encodeId=a872195e013cb, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, objectType=article, longId=188797, objectId=3aed188e972f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aed188e972f, replyNumber=0, likeNumber=63, createdTime=2020-11-15, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aed188e972f, moduleTitle=武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3aed188e972f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957012, encodeId=8e7e195e01261, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=武田制药52亿收购阿瑞雅德, objectType=article, longId=87411, objectId=7a548e411b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a548e411b5, replyNumber=0, likeNumber=66, createdTime=2017-01-23, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a548e411b5, moduleTitle=武田制药52亿收购阿瑞雅德, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7a548e411b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957011, encodeId=ee0b195e011e4, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=日本武田制药陷虚假广告丑闻, objectType=article, longId=31543, objectId=f7b43154300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f7b43154300, replyNumber=0, likeNumber=76, createdTime=2014-11-26, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f7b43154300, moduleTitle=日本武田制药陷虚假广告丑闻, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f7b43154300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957010, encodeId=588f195e010c4, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=武田制药产品研发线因Fasiglifam失败而遭受重创, objectType=article, longId=28968, objectId=778528968ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=778528968ee, replyNumber=0, likeNumber=73, createdTime=2014-11-29, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=778528968ee, moduleTitle=武田制药产品研发线因Fasiglifam失败而遭受重创, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=778528968ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1957009, encodeId=6c61195e009a1, content=<a href='/topic/show?id=8a316333963' target=_blank style='color:#2F92EE;'>#武田制药#</a>, objectTitle=武田制药糖尿病药物Fasiglifam后期临床试验效果显著, objectType=article, longId=19364, objectId=7db6193647f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7db6193647f, replyNumber=0, likeNumber=80, createdTime=2013-08-11, rootId=0, userName=ms9608593228839890, userId=6ea92500119, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7db6193647f, moduleTitle=武田制药糖尿病药物Fasiglifam后期临床试验效果显著, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7db6193647f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

武田制药

2020-05-29

侠胆医心 (审核中...)

前往app查看评论内容

2021年1月20日，国家药监局正式批准日本#武田制药#的1类降压新药#美阿沙坦#钾片（商品名称: 易达比）在我国上市，5月份，美阿沙坦正式进入临床使用，用于治疗#原发性高血压#。这是目前认为疗效最强的#降压药物#

最强降压药美阿沙坦在我国重磅上市！高血压患者福音

2023-05-14发表于上海

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

武田制药取得强劲的2021财年第三季度业绩，调高全年预测，以反映强劲发展势头

2022-08-22

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

武田制药将呈报ICLUSIG® (ponatinib) 2期OPTIC试验主要分析的阳性结果，加强填补慢性期CML治疗空白的能力

2021-05-30

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

武田制药宣布FDA接受其补充新药申请并给予优先审查，将酪氨酸激酶抑制剂ALUNBRIG用作ALK +转移性非小细胞肺癌的一线治疗

2020-11-15

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

武田制药52亿收购阿瑞雅德

2017-01-23

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

日本武田制药陷虚假广告丑闻

2014-11-26

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

武田制药产品研发线因Fasiglifam失败而遭受重创

2014-11-29

ms9608593228839890 (审核中...)

前往app查看评论内容

#武田制药#

武田制药糖尿病药物Fasiglifam后期临床试验效果显著

2013-08-11

科室
- - 订阅+
  - 更多科室
工具
服务